Manipal Hospitals IPO: ₹8,000 crore raise planned in 2026

Roadshows begin as IPO plans move forward

Temasek-backed Manipal Health Enterprises Ltd has begun meeting institutional investors ahead of its planned initial public offering (IPO), according to people aware of the matter. The Bengaluru-based hospital operator is seeking to raise up to ₹8,000 crore in primary capital, while existing investors plan to sell over 43.2 million shares. The company expects regulatory clearance in the coming weeks and is likely to target a launch window between June-end and mid-July.

The investor outreach comes at a time when India’s IPO market has been muted for several months amid global risk aversion. In some reports, the planned IPO size is described as about $1.1 billion, while a Reuters report put the filing at up to $1.17 billion. The company’s willingness to proceed despite broader volatility is being watched closely because a successful deal could help reopen the large-issue calendar.

Why timing matters: a quiet IPO market and liquidity concerns

The progress is notable because market participants have pointed to reduced liquidity for emerging markets amid geopolitical tensions in the Middle East, including the West Asia crisis. Reports said this has contributed to a period where India’s IPO market was “practically shut” for months.

At the same time, Indian equity markets were described as gradually recovering from declines linked to Middle East tensions, alongside government efforts to stabilise the fiscal outlook. Even with that recovery, the backdrop remains challenging. Reuters also reported sustained foreign investor outflows pressuring benchmarks, highlighting a “risk-off” phase and tighter liquidity conditions.

What Manipal Health has filed with SEBI

Manipal Health Enterprises filed its Draft Red Herring Prospectus (DRHP) with SEBI on March 23, 2026, according to the information provided. The proposed issue is a combination of a fresh issue and an offer for sale (OFS).

As per the DRHP details cited, the fresh issue is ₹8,000 crore. The OFS includes up to 43,227,668 equity shares by existing shareholders. Those named include Imperius Healthcare Investments Pte. Ltd, Manipal Education and Medical Group India Private Limited, TPG SG Magazine Pte. Ltd, Seventy Second Investment Company LLC, Ammar Sdn Bhd, Novo Holdings Invest Asia A/S, and Phoenix Bear Investments, LLC.

Deal size, valuation expectations, and what can still change

Multiple reports referenced a fundraise of more than $1 billion. Separately, Bloomberg reported the company is targeting a valuation of about $12 billion during roughly two weeks of meetings with domestic and international investors. That report also noted deliberations are ongoing and the offering’s size and timing could still change.

Reuters reported the IPO comprises a fresh issue to raise $152.2 million and an OFS of about 43.2 million shares by existing investors such as Temasek, TPG, Manipal Education and Novo Holdings. It also cited two sources saying existing investors plan to sell up to ₹30 billion worth of shares. These figures underscore that the final structure may be discussed across different sources, but the fresh issue component of ₹8,000 crore is consistently referenced.

Use of proceeds: debt repayment and Sahyadri acquisition funding

Manipal Health said it plans to use IPO proceeds for repayment of outstanding borrowings and to fund its acquisition of Sahyadri Hospitals, according to the filing. The Sahyadri acquisition was described as a $100 million deal.

This intended use is relevant for investors assessing the balance between deleveraging and growth spending. A portion of proceeds earmarked for debt repayment can lower interest burden, while funding an acquisition can add scale, but also raises questions about integration and execution timelines. The company has positioned itself as an active consolidator in India’s hospital sector, as noted in the coverage.

What investor meetings suggest about demand

One person cited in the material said the company decided to proceed with its IPO plans notwithstanding market conditions. Another person said initial discussions suggest demand for asset-backed companies with steady cash flows.

Hospitals typically fall into that category due to physical assets and recurring healthcare demand, although performance varies by location and specialty mix. The narrative in the material also notes rising demand for specialised medical care in India, which is one of the themes around the IPO.

Book-running lead managers named in the DRHP

The DRHP lists a large syndicate of book-running lead managers. These include Kotak Mahindra Capital Company Limited, Axis Capital Limited, Goldman Sachs (India) Securities Private Limited, Jefferies India Private Limited, J.P. Morgan India Private Limited, UBS Securities India Private Limited, and DBS Bank India Limited.

A broad manager group is common for larger offerings that aim to reach both domestic and international pools of capital, especially when markets are volatile and issuers want distribution flexibility.

Market backdrop: foreign outflows and risk sentiment

Reuters reported foreign investors have withdrawn more than $11.65 billion from Indian stocks so far in 2026, including more than $10.17 billion in March alone, citing depository data. Such outflows tend to raise the bar for new listings, particularly larger ones that rely on global institutions.

This backdrop is a key variable for Manipal Health’s timetable. While the company is preparing for a June-end to mid-July window, the final launch decision will likely depend on market stability, investor risk appetite, and the strength of pre-marketing feedback.

Key facts snapshot

Timeline to watch

Why this IPO matters for India’s primary market

Manipal Health’s move is being tracked because it tests institutional demand in a period marked by geopolitical risk and tight liquidity. Coverage noted the IPO market had been largely quiet for months, and a large healthcare listing could serve as a sentiment indicator for other issuers.

The offering’s structure also reflects two objectives at once: bringing in primary capital through a ₹8,000 crore fresh issue and providing an exit route to existing shareholders through an OFS of over 43.2 million shares. If SEBI clearance comes on schedule, the company’s next milestones will be finalising price bands, completing formal marketing, and confirming the exact launch dates within the June-end to mid-July window.